The 16-year immunization visit should include:
- Administration of the second dose of MenACWY (quadrivalent meningococcal conjugate vaccine)
- Administration of the influenza vaccine, which is recommended annually (for each influenza season)
- A discussion about MenB vaccine, which helps to protect against a fifth type of meningococcal bacteria
- Catch-up for the HPV series, if indicated, which is recommended to be completed by 11–12 years of age
- Catch-up for the Tdap booster, if indicated, which is also recommended for all eligible adolescents 11–12 years of age
The 16-year adolescent immunization platform is supported by a number of professional medical societies, including the Immunization Action Coalition, American Academy of Family Physicians Foundation, National Foundation for Infectious Diseases, the Society for Adolescent Health and Medicine, and UNITY Consortium, among others.
The NMA encourages all healthcare professionals to review and adopt the Immunization Action Coalition’s standing orders for adolescent immunization. We have linked the standing orders for administering MenACWY and MenB vaccines to adolescents.
The Adolescent Immunization Initiative developed a rationale for a 16-year immunization platform in the form of a white paper, which is linked for your convenience.
Brought to you as a public health service by the National Meningitis Association, Inc. (NMA) and Sanofi Pasteur Inc. The NMA does not endorse specific products or brands. NMA policies restrict funders from controlling content.